Abstract
Machine-learning (ML) classification may offer a promising approach for treatment response prediction in patients with major depressive disorder (MDD) undergoing non-invasive brain stimulation. This analysis aims to develop and validate such classification models based on easily attainable sociodemographic and clinical information across two randomized controlled trials on transcranial direct-current stimulation (tDCS) in MDD. Using data from 246 patients with MDD from the randomized-controlled DepressionDC and ELECT-TDCS trials, we employed an ensemble machine learning strategy to predict treatment response to either active tDCS or sham tDCS/placebo, defined as ≥ 50% reduction in the Montgomery-Åsberg Depression Rating Scale at 6 weeks. Separate models for active tDCS and sham/placebo were developed in each trial and evaluated for external validity across trials and for treatment specificity across modalities. Additionally, models with above-chance detection rates were associated with long-term outcomes to assess their clinical validity. In the DepressionDC trial, models achieved a balanced accuracy of 63.5% for active tDCS and 62.5% for sham tDCS in predicting treatment responders. The tDCS model significantly predicted MADRS scores at the 18-week follow-up visit (F(1,60) = 4.53, pFDR = .037, R2 = 0.069). Baseline self-rated depression was consistently ranked as the most informative feature. However, response prediction in the ELECT-TDCS trial and across trials was not successful. Our findings indicate that ML-based models have the potential to identify responders to active and sham tDCS treatments in patients with MDD. However, to establish their clinical utility, they require further refinement and external validation in larger samples and with more features.
Competing Interest Statement
GB, SG, LB, ED, DK, UV, KW, JW, AF, CN, PZ, TK, CS, NK and AB have no competing interests to declare. CP has received grants from the German Federal Ministry of Education and Research (01KG2003, 01EE1407H, and 01EE1403D) and the Deutsche Forschungsgemeinschaft (PL 525/4-1, PL 525/6-1, and PL 525/6-1) and holds stock options for PsyKit (Tuebingen, Germany). BL has received grants from Bayhost, the EU (European School for Interdisciplinary Tinnitus Research [722046] and the Unification of Treatments and Interventions for Tinnitus Patients [848261]), and Neuromod; consulting fees from Neuromod, Decibel Therapeutics, Schwabe, Rovi, Sound Therapeutics, Sonovam, and Sea Pharma; payments from Schwabe, Neuromod, and Desyncra for lectures; payments from Schwabe for expert testimony; has a pending patent for neuronavigated transcranial magnetic stimulation coil positioning for the treatment of tinnitus; participated on a data safety monitoring board or advisory board for the Technical University of Munich (Nicstim) and Neuromod (TENT A2, TENT A3); has a chair on the executive committee of the German Society for Brain Stimulation in Psychiatry and has a fiduciary role in the Tinnitus Research Initiative; has stock or stock options from Sea Pharma; and has received free rental equipment from Magventure, Deymed, and Necstim. LF has received author royalties for book chapters from Wiley-Blackwell, Georg Thieme Verlag, Urban & Fischer Verlag, and Elsevier; and payments for classes from the German Sleep Society, the European Sleep Research Society, and Medical Association Freiburg. DK has received a grant from the Manfred-Strohscheer Foundation for the Activity of Cerebral Networks, Amyloid and Microglia in Alzheimers Disease (ActiGliA) project and has received travel and hotel expenses for an invited talk from the EU-funded Stimulation in Pediatrics project. MB has received consulting fees from Parexel and Bayer and payments for lectures from Johnson & Johnson. LF has received author royalties for book chapters from Wiley-Blackwell, Georg Thieme Verlag, Urban & Fischer Verlag, and Elsevier; and payments for classes from the German Sleep Society, the European Sleep Research Society, and Medical Association Freiburg. FP has received grants from the German Research Foundation (BR 4264/6-1) and the German Federal Ministry of Education and Research (01EW1903); consulting fees from Brainsway (Jerusalem, Israel) as a member of the European Scientific Advisory Board and from Sooma (Helsinki, Finland) as a member of the International Scientific Advisory Board; honoraria for workshops from Mag&More (Munich, Germany) and honoraria for lectures from the NeuroCare Group and Brainsway; and has received equipment from Mag&More, the NeuroCare Group, and Brainsway.
Funding Statement
This research was funded by grant 01EE1403E within the German Center for Brain Stimulation research consortium by the German Federal Ministry of Education and Research and supported within the initial phase of the German Center for Mental Health (Deutsches Zentrum fuer Psychische Gesundheit [DZPG], grant 01EE2303A). GB was supported by two internal grants for young researchers from the Medical Faculty of LMU Munich (FoeFoLe, grant number 1127; FoeFoLe+, grant number CS063). JW was supported by an internal grant for young researchers from the Medical Faculty of LMU Munich (FoeFoLe, grant number 1150).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Medical Faculty of the Ludwig-Maximilian-University Munich gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
